Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer (RADI-S)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06044961 |
Recruitment Status :
Completed
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning.
The study aims to apply radiomics for the prediction of response to neoadjuvant therapy.
Condition or disease | Intervention/treatment |
---|---|
Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction | Radiation: CT scan |
Study Type : | Observational |
Actual Enrollment : | 80 participants |
Observational Model: | Other |
Time Perspective: | Retrospective |
Official Title: | Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer |
Study Start Date : | January 1, 2005 |
Actual Primary Completion Date : | August 30, 2022 |
Actual Study Completion Date : | November 15, 2022 |
- Radiation: CT scan
All pre-operative CT scan collected
- Use of radiomics [ Time Frame: 1 month ]Apply radiomics for predicting response to neoadjuvant therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients with locally advanced stomach cancer undergoing neoadjuvant chemotherapy and gastrectomy between January 2005 and August 2022
Exclusion Criteria:
- Siewert 1 tumors;
- Patients who have received neoadjuvant with the addition of a biological drug;
- Patients who have received radiotherapy;
- Patients without staging CT scan or with insufficient image quality in terms of phases performed, pixel spacing, slide thickness (mandatorily: > 5 mm) or artefacts.
Responsible Party: | Agnes Annamaria, MD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
ClinicalTrials.gov Identifier: | NCT06044961 |
Other Study ID Numbers: |
5297 |
First Posted: | September 21, 2023 Key Record Dates |
Last Update Posted: | September 21, 2023 |
Last Verified: | September 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
stomach cancer esophagogastric junction. locally advanced carcinoma of the stomach radiomics |
Stomach Neoplasms Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms |
Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Stomach Diseases |